CGTV (China Television) story on Biodesix's agreement with Bioyong, and why lung cancer tests are needed in China
GenomeWeb story: Biodesix receives two positive coverage decisions for VeriStrat
Results from a analysis suggest VeriStrat may be selective of positive clinical response for ficlatuzumab plus gefitinib over gefitinib alone.
Veristart passed a key clinical trial that shows it can give physicians a better idea of what to do next after the first round of treatment for NSCLC.
Lung cancer specialist Karen Reckamp, M.D., is tired of seeing what the disease does to her patients. It all comes down to a blood test called VeriStrat.
Biodesix’s business model is based on two strands–clinical diagnostics and companion diagnostics; Tests based on the presence or absence of a biomarker.
Biodesix's Jeffrey Bojar discusses Evolution of Translational Omics: Lessons Learned and the Path Forward and the rigorous framework it provides.
Trial Shows Biodesix Assay Predicts Breast Cancer Response to Femara (Genetic Engineering News)
Biodesix is looking to forge pharmaceutical partnerships to increase adoption of the test Veristrat.
CBSA's May BioBreakfast allowed two of Colorado's 2009 Bioscience success stories to share their stories. First up was Biodesix, in the diagnostic space.